AAV9.LAMP2B基因治疗Danon病的1期研究
这项1期研究评估单次输注RP-A501(含LAMP2B转基因的AAV9载体)治疗Danon病男性患者的安全性和疗效。7例患者接受输注并接受短暂免疫调节方案,24至54个月随访期间,6例基线左室射血分数正常者出现心脏LAMP2蛋白表达及左室质量指数较基线降低或稳定。结论认为单次输注RP-A501似乎安全,并与心脏LAMP2表达及临床改善证据相关。
要点
- 7例Danon病男性患者接受单次RP-A501输注,随访24至54个月全部存活。
- 6例基线左室射血分数正常者出现心脏LAMP2蛋白表达及左室质量指数较基线降低或稳定。
- 1例发生补体介导的血栓性微血管病(4级),3例出现糖皮质激素相关Danon病骨骼肌病加重(3级)。
核心结论
- 单次输注RP-A501似乎安全,并与心脏LAMP2表达及24至54个月期间的临床改善证据相关。
研究设计与样本
- 1期研究,评估单次输注RP-A501(含LAMP2B转基因的重组腺相关病毒血清型9)的安全性和疗效。
- RP-A501输注给予7例Danon病男性患者:5例年龄15岁及以上,2例年龄11至14岁。
- 所有患者接受泼尼松、他克莫司或西罗莫司及利妥昔单抗的短暂免疫调节方案。
主要发现
- 1例发生补体介导的血栓性微血管病(4级),伴血小板减少和急性肾损伤。
- 3例出现糖皮质激素相关Danon病骨骼肌病加重(3级)。
- 1例基线左室收缩功能障碍者出现进行性心力衰竭,输注后5个月接受移植。
- 6例基线左室射血分数正常者出现心脏LAMP2蛋白表达、左室质量指数较基线降低或稳定、左室射血分数保持,以及心脏肌钙蛋白I和N末端B型利钠肽原水平降低或稳定。
- 在24至54个月时,所有患者存活,副作用完全消退。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Danon disease is a rare, X-linked, monogenic cardiomyopathy caused by mutations in the lysosomal-associated membrane 2 gene (LAMP2), which encodes the LAMP2 protein. In male patients, the predominant phenotype is progressive cardiac hypertrophy, cardiac dysfunction, and early death. There are no directed therapies for the disease. METHODS: In this phase 1 study, we evaluated the safety and efficacy of a single infusion of RP-A501, a recombinant adeno-associated virus serotype 9 containing the transgene LAMP2B, which encodes an isoform of LAMP2. The primary outcomes were the safety and toxic effects of RP-A501, myocardial LAMP2 transduction and protein expression, stabilization of or reduction in heart-failure symptoms, and stabilization of or improvement in cardiac structure and function. Key secondary outcomes were sustained reduction in or stabilization of symptoms, immunologic response to RP-A501, end-stage heart failure, and overall survival. Exploratory outcomes included improvement in serologic markers of cardiac disease, patient-reported outcomes, and quality-of-life assessments. RESULTS: RP-A501 infusion was administered to seven male patients with Danon disease: five who were 15 years of age or older and two who were between 11 and 14 years of age. All the patients received a transient immunomodulatory regimen of prednisone, tacrolimus or sirolimus, and rituximab. Phase 1 data over 24 to 54 months, including interim data from a long-term follow-up study, are reported here. One patient had complement-mediated thrombotic microangiopathy (grade 4) with thrombocytopenia and acute kidney injury. Three patients had glucocorticoid-related exacerbation (grade 3) of Danon disease-related skeletal myopathy. One patient with left ventricular systolic dysfunction at baseline had progressive heart failure and underwent transplantation 5 months after infusion. In the six patients with normal left ventricular ejection fraction at baseline, we observed cardiac LAMP2 protein expression and a reduction from baseline in or stabilization of the left ventricular mass index, preservation of left ventricular ejection fraction, and reduction in or stabilization of the levels of cardiac troponin I and N-terminal pro-B-type natriuretic peptide. At 24 to 54 months, all the patients were alive, with complete resolution of side effects. CONCLUSIONS: A single infusion of RP-A501 appeared to be safe and was associated with cardiac LAMP2 expression and evidence of clinical improvement over a period of 24 to 54 months. (Funded by Rocket Pharmaceuticals; ClinicalTrials.gov number, NCT03882437.).
引用
- Greenberg B, Taylor M, Adler E, et al. Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N Engl J Med. 2024. PMID: 39556016. doi:10.1056/NEJMoa2412392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。